Glenmark Pharma Q1

Cons Net Profit Up 47% At Rs 333.4 Cr Vs Rs 226.8 Cr (YoY)

Cons Revenue Up 20% At Rs 2,363 Cr Vs Rs 1,969 Cr (YoY)

Cons EBITDA Up 52.3% At Rs 577.4 Cr (YoY)

Cons EBITDA Margin At 24.4% Vs 19.2% (YoY)